Exploring unique proteins on the surface of ultra-rare cancers to find new treatment targets
Official title: Integrative proteogenomics for elucidation of tumor-specific cell surface proteomes in ultra-rare cancers
Funded at Sloan-Kettering Inst Can Research · NIH-11067224 · Data updated 2026-11-12
This study is looking at very rare cancers, like rhabdoid tumors and desmoplastic small round cell tumors, to find new ways to treat them by identifying specific proteins on the tumors that could help improve treatment and survival for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 5, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,496,492 |
| NIH project number | 1U01FD008299-01 |
| Project ID | NIH-11067224 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rhabdoid tumors or desmoplastic small round cell tumors.
✕Less likely to help
Patients with more common types of cancer or those without a diagnosis of the specific ultra-rare cancers being studied may not benefit from this research.
What this research studies
This research focuses on understanding ultra-rare cancers, specifically rhabdoid tumors and desmoplastic small round cell tumors (DSRCT), which are difficult to treat due to their rarity and resistance to therapy. By using advanced genomic and proteomic technologies, the project aims to identify specific proteins on the surface of these tumors that could serve as new targets for therapy. The research will analyze a large cohort of patients to construct detailed maps of tumor-specific proteins, which may lead to improved treatment options and survival rates for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with ultra-rare cancers.
How similar studies have gone: While research on ultra-rare cancers is limited, similar integrative approaches in other cancer types have shown promise in identifying new therapeutic targets.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Kentsis, Alex — Sloan-Kettering Inst Can Research
- Study coordinator: Kentsis, Alex
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.